Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2023 | Treatment options and unmet needs in pediatric patients with R/R CML

Erica Brivio • 10 Jun 2023
EHA 2023
Chronic Myeloid Leukemia Leukemia Asciminib Bosutinib Dasatinib Imatinib Nilotinib Ponatinib

Erica Brivio, MD, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands, outlines treatment options for pediatric patients with chronic myeloid leukemia (CML) who relapse after first- and second-line treatment, emphasizing the importance of determining whether some pediatric patients can attempt treatment discontinuation with TKIs. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Erica Brivio

1:41
Toxicity profile of bosutinib in pediatric patients with R/R CML
Erica Brivio • 10 Jun 2023
1:04
Phase I/II study of bosutinib in newly diagnosed & resistant/intolerant pediatric patients with CML
Erica Brivio • 10 Jun 2023
4:08
Inotuzumab ozogamicin for treating pediatric R/R ALL
Erica Brivio • 10 Dec 2020

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals